Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
In excess of 80,000 patients are diagnosed with Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) and in excess of 200,000 patients are living with these diseases. The more aggressive Non-Hodgkin’s Lymphomas are cured 45% of the time, while, as of today, Chronic Lymphocytic Leukemia is not curable. That is the task of clinical research and new drug development.
Gabrail Cancer Center, a community based cancer treatment and research center located in Canton, Ohio is announcing its commitment to enhancing the process of new drug development for NHL and CLL by dedicating a special section of the Gabrail Cancer Center and its operations for this novel cause.
Currently, GCC is providing patients with NHL and CLL access to more than 10 clinical trials dedicated to NHL and CLL. The GCC staff is committed to providing accessible, state-of-the-art cancer research to our local community and the surrounding areas.
New anti-cancer drug development has only one path: clinical trial access to patients who need them. Most patients with NHL and CLL would qualify for one of the numerous clinical trials offered at the Gabrail Cancer Center. To succeed in this endeavor, helping cancer patients and the community at large, we need the help of everyone to propagate the availability of these innovative clinical trials. The effort of every physician, family member, and the patients themselves is critical to make this project a success.